Skip to main content
. 2022 Apr 11;9:849474. doi: 10.3389/fcvm.2022.849474

Table 5.

Base-case analysis result comparing warfarin and DOACs.

Strategy Cost ($) Incremental cost QALY ICER ($/QALY)
Warfarin 2,874 Ref. 10.83 Ref.
Rivaroxaban 6,379 3,505 10.95 29,743.99
Apixaban 5,151 2,276 11.10 8,426.71
Dabigatran 5,761 2,886 10.49 −8,483.04
Edoxaban 5,851 2,976 10.99 18,483.55

ICER, incremental cost-effectiveness ratio; QALY, quality adjusted life year; DOACs, direct oral antagonist oral anticoagulants.